Accelerate Early-Phase Clinical Studies in Australia

The Australian Advantage refers to the strategic benefits of conducting early-phase clinical studies in Australia. For eligible studies, Australia’s pathway can reduce regulatory friction, with no IND required before study start. The data completed in Australia is globally accepted as an OECD country, with quality standards of global regulatory bodies like: FDA, EMA. Eligible companies may also access Australia’s 43.5% refundable R&D tax incentive, supporting capital efficiency during early development. 

Australia is a trusted and established market for early-phase clinical trials, with a streamlined regulatory environment, efficient HREC approval process, strong data and intellectual property privacy laws, and access to experienced clinical research institutions and trial facilities. Sponsors can also benefit from diverse participant populations, access to medical and scientific KOLs, and favorable seasonal differences for vaccine, allergy, and infectious disease studies.

360biolabs, a BioAgilytix company, supports sponsors using the Australian Advantage to progress Phase 1 studies efficiently in Australia. Sponsors can then expand into Phase 2 with support from BioAgilytix’s global laboratory network, helping maintain bioanalytical continuity across development stages.

Select Early-Phase Australian Advantage (360biolabs) in our Speak to a Scientist form OR contact the 360biolabs team to discuss your early-phase clinical study, bioanalytical requirements, timelines, and whether Australia may be an appropriate location for your program: 360biolabs, Connect with Us